I read with interest the article on the prognostic value of exercise testing after acute myocardial infarction (MI) reported by Domínguez et al. [1] . We have previously reported [2] our experience with early exercise testing and 4-year follow-up results in a cohort of patients admitted with acute coronary syndrome (of whom 65% had a confirmed MI) from the pre-thrombolytic era (patients recruited 1982-1984) also in the context of only rare intervention during follow-up.
Multiple logistic regression analysis found that total mortality and nonfatal infarctions could be predicted by (a) inability to perform early stress testing (event-free survival for patients exercise tested 79·5% vs 56·9% for patients not eligible for testing; relative risk (RR) 1·40, 95% confidence interval (CI) 1·10-1·78, P=0·01), and (b) low exercise capacity (RR 1·44, CI 1·08-1·93, P=0·034). ST segment shift did not predict mortality or infarction. The similar results in the present study, with a larger number of patients studied over a longer time, is reassuring and should encourage continued routine use of this simple and safe test in the evaluation of patients with acute coronary syndrome and acute myocardial infarction. 
A reply
We thank Dr Rønnevik for his comments on our article [1] . Early works, such as the one published by Rønnevik and Von der Lippe [2] are very valuable because they alert us to the real value of exercise testing.
One of the main conclusions of the study of Rønnevik et al. [2] , namely that work capacity is associated with poor outcome in patients suspected of having myocardial infarction, fits well with our results and has been illustrated by the early meta-analysis [3] , as pointed out by Ashley and Froelicher [4] . Furthermore, the weak prognostic value of the presence of ischaemia during the test has been assessed both pre and post the thrombolytic era [3, 5] . Our study, of a large unselected population with confirmed myocardial infarction [1] , adds to current knowledge demonstrating that prognostic associations are present after 15 years follow-up. Similar to the cohort followed by Rønnevik et al.
[2] , the inability to perform the test is an even stronger predictor of poor outcome than information obtained during the test.
In our opinion it is worth highlighting the poor prognosis of patients unable to perform an exercise test [1, 2] shortly after a myocardial infarction so that more can be done to improve and prolong their prognosis. 
Dissent from the consensus on the redefinition of myocardial infarction
Many clinicians will agree with the views of the dissenter [1] that the consensus redefinition of myocardial infarction [2] ignores many fatal cases, will cause diagnostic confusion and chaos in mortality and morbidity statistics, and will result in problems for insurance and subsequent employment of surviving patients.
Most clinical diagnoses of myocardial infarction have been based on the 'two out of three' criteria using total creatine kinase (CK) activity as the serum marker. The reasons for the lack of specificity of CK are well understood, and the two out of three criteria are sufficiently robust to allow conformity of diagnostic criteria among different observers. Consequently nearly all knowledge derived from clinical trials and observational studies of myocardial infarction has been derived from these criteria.
As well as removing some fatal cases (because troponin levels do not become elevated until about 6 h after the onset), reliance on troponin will add many new ones. Quite apart from elevations caused by coronary angioplasty, unstable angina is now more common in hospitals than myocardial infarction, and troponin but not CK levels are raised in 30-40% of these [3, 4] . The pathogenesis of these fatal cases which will now be labelled myocardial infarction is almost certainly different from that of completed infarction as previously defined.
As the consensus document states [2] , tiny infarcts occurring after angioplasty are probably caused by microemboli from disruption of an unstable atheromatous lesion. Patients who 0195-668X/01/221626+02 $35.00/0
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